Macquarie Group
JANX icon

Macquarie Group’s Janux Therapeutics JANX Stock Holding History

Macquarie Group’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-76,601
Closed -$1.87M – 1179
2025
Q3 		$1.87M Hold
76,601
– – ﹤0.01% 1190
2025
Q2 		$1.77M Hold
76,601
– – ﹤0.01% 1260
2025
Q1 		$2.07M Hold
76,601
– – ﹤0.01% 1213
2024
Q4 		$4.1M Hold
76,601
– – 0.01% 993
2024
Q3 		$3.48M Hold
76,601
– – ﹤0.01% 1057
2024
Q2 		$3.21M Buy
76,601
+16,601
+28% +$779K ﹤0.01% 1089
2024
Q1 		$2.26M Buy
+60,000
New +$1.31M ﹤0.01% 1186

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Macquarie Group's JANX Position: Q4 2025 in Review

Macquarie Group sold out of Janux Therapeutics (JANX) in Q4 2025, closing a stake of 76,601 shares — an estimated $1.87M sold.

Macquarie Group first reported a position in JANX in Q1 2024 and held it in 7 quarters. The position peaked at $4.1M in Q4 2024. 176 funds tracked by Wall St. Rank hold JANX as of Q4 2025.

  • Macquarie Group reported no remaining Janux Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Macquarie Group sold 76,601 Janux Therapeutics shares in Q4 2025, an estimated $1.87M.
  • Macquarie Group first reported a position in Janux Therapeutics in Q1 2024 and held it in 7 quarters.
  • Macquarie Group's Janux Therapeutics position peaked at $4.1M in Q4 2024.
  • 176 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.